TABLE 1

Exposures of APX001A following oral dosing of APX001 in the presence or absence of ABT pretreatment

APX001
dose (mg/kg)
ABT dose
(mg/kg; dosing frequency)
Avg APX001A
AUCa (μg·h/ml)
AUC ratio
(with ABT/without ABT)
26None2.77 ± 0.23
100; QD41.50 ± 8.0915.0
None2.48 ± 1.26
25; QD31.68 ± 3.6012.8
50; QD40.39 ± 1.7316.3
50; BID38.20 ± 7.0015.4
52None5.30 ± 0.9814.3
25; QD52.00 ± 35.469.8
50; QD94.29 ± 12.4317.8
50; BID92.41 ± 7.7017.4
  • a Time course for the Fast PK experiment: 0.083 0.5, 2, 4, 8, and 24 h postdose of 26 mg/kg prodrug (n = 3 per time point). AUC is the area under the curve of the analyte, calculated from T = 0 to the last measurable concentration.